Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 12:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Baxter Healthcare Corporation Clear all

Conditions: Bleeding Active
Interventions: CELSTAT, Surgicel Original; Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 19
States / cities: Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 14 more

Conditions: Blood Pressure
Interventions: ModPG3 Investigational Device, Invasive Reference Equipment; Device
Lead sponsor: Welch Allyn; Industry
Eligibility: Up to 3 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Spinocerebellar Ataxias
Interventions: Intravenous Immune Globulin (IVIG); Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions: CD34-positive cells, Saline and 5% autologous plasma; Biological
Lead sponsor: Losordo, Douglas, M.D.; Individual
Eligibility: 21 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 12
States / cities: Birmingham, Alabama • Gainsville, Florida • Orlando, Florida + 9 more

Conditions: Subjects Requesting and Requiring an Open Rhinoplasty
Interventions: ARTISS human fibrin sealant; Biological
Lead sponsor: DeNova Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parenteral Nutrition
Interventions: ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Deep Partial or Full Thickness Wounds
Interventions: Fibrin Sealant, ARTISS 4IU/ml VH SD, Staples; Biological · Other
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: Up to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 17
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more

Conditions: Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
Interventions: MN 4000; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Critical Illness, Acute Respiratory Failure
Interventions: Olimel (5.7%E / N9E); Drug
Lead sponsor: Clinical Evaluation Research Unit at Kingston General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Boulder, Colorado • St Louis, Missouri • Cleveland, Ohio + 3 more

Conditions: Atelectasis, Pulmonary Complications
Interventions: MetaNeb® System; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: 18 Years and older
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Burlington, Massachusetts • Charlotte, North Carolina • Philadelphia, Pennsylvania

Conditions: Dehydration, Gastroenteritis
Interventions: multiple electrolyte solution, saline; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 6 Months to 10 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Atlanta, Georgia • Cincinnati, Ohio • Cleveland, Ohio + 3 more

Conditions: Adhesion
Interventions: ADEPT; Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Bioequivalance
Interventions: Iron Sucrose Injection, Venofer Injection; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Cefazolin; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Loss
Interventions: Hemostatic Matrix; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: Not listed
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Bleeding
Interventions: FloSeal Matrix; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diseases, Metabolic, Insulin Sensitivity
Interventions: Intralipid, ClinOleic, Dextrose, Saline (control); Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pressure Ulcers
Interventions: P500 Mattress; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: 19 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Febrile Illness
Interventions: Connex CVSM with Timmy3 module; Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 1 Day to 99 Years
Enrollment: 373 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Fayetteville, Georgia • Mankato, Minnesota • Buffalo, New York + 2 more

Conditions: Intraoperative Blood Loss, Thoracolumbar Spine Surgery
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: End Stage Renal Disease
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 100 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Renal Failure Chronic Requiring Hemodialysis
Interventions: Heparin dose titration; Procedure
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Healthy
Interventions: recombinant human hyaluronidase; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Refractory Ischemia
Interventions: Not listed
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding

ModPG3 Neo-Infant ISO 81060-2:2018

An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias

Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia

A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty

Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN

Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

MN4000 for Treatment of CF and MND Patients in the Home Setting

Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)

Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications

Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis

PMCF Study for ADEPT® in LaparoscopicGynecologic Surgery

Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects

Cefazolin PK Study 3g vs 2g

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)

Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers

Pilot Study of Incidence and Change in Existing Pressure Ulcers: TC500 Bed Compared With Standard Beds

Timmy3 Module Clinical Accuracy ISO 80601-2-56:2017 + A1 2018

The Utility of the Validated Intraoperative Bleeding Scale in Spine Surgery

Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis

A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

Quality of Life in Patients With Refractory Angina